Wealthfront Advisers LLC Takes $3.40 Million Position in Humana Inc. $HUM

Key Points

• Wealthfront Advisers acquired 8,549 Humana shares worth approximately $3.4 million during the second quarter. Institutional investors and hedge funds collectively own 92.38% of Humana.
• Humana reported quarterly earnings of $7.61 per share, beating estimates of $7.27, while revenue rose 26.2% year over year to $40.89 billion.
• Humana shares recently traded at $380.48, up 0.7%. Analysts maintain a consensus “Hold” rating with an average price target of $395.22, despite mixed recommendations.

Wealthfront Advisers LLC acquired a new position in shares of Humana Inc. (NYSE:HUM - Free Report) in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 8,549 shares of the insurance provider's stock, valued at approximately $3,396,000.

Several other hedge funds also recently made changes to their positions in the company. Wilkerson Advisory Group LLC boosted its holdings in Humana by 24.6% in the second quarter. Wilkerson Advisory Group LLC now owns 167 shares of the insurance provider's stock worth $66,000 after purchasing an additional 33 shares during the period. Bogart Wealth LLC increased its stake in shares of Humana by 192.0% in the second quarter. Bogart Wealth LLC now owns 73 shares of the insurance provider's stock valued at $29,000 after purchasing an additional 48 shares during the period. Fiduciary Alliance LLC raised its stake in Humana by 0.9% during the 1st quarter. Fiduciary Alliance LLC now owns 5,628 shares of the insurance provider's stock valued at $976,000 after acquiring an additional 49 shares in the last quarter. Sanctuary Advisors LLC raised its stake in shares of Humana by 1.6% during the fourth quarter. Sanctuary Advisors LLC now owns 3,389 shares of the insurance provider's stock valued at $868,000 after purchasing an additional 52 shares in the last quarter. Finally, Horizon Investments LLC raised its position in shares of Humana by 2.5% during the 4th quarter. Horizon Investments LLC now owns 2,236 shares of the insurance provider's stock worth $573,000 after buying an additional 55 shares in the last quarter. Institutional investors and hedge funds own 92.38% of the company's stock.

Humana Trading Up 0.7%

NYSE:HUM opened at $380.48 on Friday. Humana Inc. has a 1-year low of $163.11 and a 1-year high of $428.88. The stock has a fifty day simple moving average of $383.38 and a 200 day simple moving average of $280.90. The firm has a market capitalization of $45.69 billion, a price-to-earnings ratio of 36.00, a price-to-earnings-growth ratio of 2.16 and a beta of 0.72. The company has a quick ratio of 1.74, a current ratio of 1.74 and a debt-to-equity ratio of 0.62.

Humana (NYSE:HUM - Get Free Report) last issued its earnings results on Wednesday, July 29th. The insurance provider reported $7.61 EPS for the quarter, topping the consensus estimate of $7.27 by $0.34. The business had revenue of $40.89 billion during the quarter, compared to analysts' expectations of $40.58 billion. Humana had a return on equity of 11.20% and a net margin of 0.88%.Humana's revenue was up 26.2% compared to the same quarter last year. During the same quarter last year, the firm posted $6.27 earnings per share. Sell-side analysts forecast that Humana Inc. will post 9.08 earnings per share for the current year.

Analyst Upgrades and Downgrades

HUM has been the subject of a number of research analyst reports. The Goldman Sachs Group upped their price target on shares of Humana from $158.00 to $195.00 and gave the stock a "sell" rating in a research note on Thursday, April 30th. Seaport Research Partners cut Humana to a "neutral" rating in a report on Wednesday, May 20th. Raymond James Financial lowered Humana from an "outperform" rating to a "market perform" rating in a research note on Thursday, July 30th. Robert W. Baird set a $390.00 price target on Humana in a research report on Thursday, July 30th. Finally, Evercore raised Humana from an "in-line" rating to an "outperform" rating and set a $480.00 price objective on the stock in a research note on Wednesday, July 29th. Fourteen equities research analysts have rated the stock with a Buy rating, fifteen have given a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus price target of $395.22.

Humana Profile

Humana Inc NYSE: HUM is a health insurance company headquartered in Louisville, Kentucky, that primarily serves individuals and groups across the United States. The company is best known for its Medicare business, offering Medicare Advantage plans and prescription drug (Part D) coverage, alongside a range of commercial and employer-sponsored group health plans. Humana's products are designed to cover medical, behavioral health and pharmacy needs for members, with particular emphasis on seniors and Medicare-eligible populations.

In addition to traditional insurance products, Humana provides care-management and wellness services intended to support chronic-condition management, preventive care and care coordination.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source